SUTRO BIOPHARMA, INC. Operating Lease Liability
SUTRO BIOPHARMA, INC. (STRO) had Operating Lease Liability of $10.78 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-12
- 2026-06-30: Operating Lease, Liability $10.78M.
- 2026-03-31: Operating Lease, Liability $13.63M.
- 2025-12-31: Operating Lease, Liability $15.67M.
- 2025-09-30: Operating Lease, Liability $17.66M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $10.78M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $13.63M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $15.67M 10-K · filed 2026-03-23 |
| 2025-09-30 | $17.66M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $19.59M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $21.40M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $23.15M 10-K · filed 2025-03-13 |
| 2024-09-30 | $24.86M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $26.53M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $28.07M 10-Q · filed 2024-05-13 |
| 2023-12-31 | $29.57M 10-K · filed 2024-03-25 |
| 2023-09-30 | $31.04M 10-Q · filed 2023-11-13 |
| 2023-06-30 | $32.46M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $33.32M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $34.16M 10-K · filed 2023-03-30 |
| 2022-09-30 | $33.67M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $33.19M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $32.71M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $32.26M 10-K · filed 2022-02-28 |
| 2021-09-30 | $33.52M 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |